摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-aminooxy-3-(1-piperidinyl)-propane

中文名称
——
中文别名
——
英文名称
1-aminooxy-3-(1-piperidinyl)-propane
英文别名
O-(3-piperidino-propyl)-hydroxylamine;O-[3-(1piperidyl)propyl]-hydroxylamine;O-(3-piperidin-1-ylpropyl)hydroxylamine
1-aminooxy-3-(1-piperidinyl)-propane化学式
CAS
——
化学式
C8H18N2O
mdl
MFCD11613806
分子量
158.244
InChiKey
MZNXUBVGQOSWEJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    11
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    38.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-aminooxy-3-(1-piperidinyl)-propane 以70.8%的产率得到N-pentyl-N'-(3-piperidino-propoxy)-urea
    参考文献:
    名称:
    Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions
    摘要:
    本发明提供了一种由通式表示的新型羟胺衍生物:其中:X为O、-NH,或者是一个由通式NR'表示的基团,其中R和R'分别独立地选自烷基、环烷基、苯基烷基、苯基(可选择地取代卤素、卤代烷基、烷基、烷氧基或硝基)和含氮杂环;R^1为H或烷酰基,R^2为H或羟基(可选择地酰化为烷酰基),R^3为由通式-NR^4R^5表示的基团,其中R^4和R^5独立地选自H、烷基,以及由通式-CO-NH-R表示的基团,其中R如上所定义,或者当R^4和R^5结合在一起形成一个5-至7-成员的杂环,该杂环可选择地含有一个额外的氮、氧和硫中选择的杂原子,并且可选择地取代为烷基或苯基烷基。此外,还提供了上述化合物的药学上可接受的酸盐,以及含有这些化合物或它们的酸盐盐作为活性成分的药物组合物。该发明的化合物已被证明具有抗缺血作用。
    公开号:
    US06002002A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS D'IMIDAZOQUINOXALINE SUBSTITUÉS ET LEURS UTILISATIONS
    申请人:IMPACT THERAPEUTICS INC
    公开号:WO2021047646A1
    公开(公告)日:2021-03-18
    The disclosure provides substituted imidazo [1, 5-a] quinoxaline and related compounds as kinase inhibitors, and their uses. Specifically, the disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof or prodrugs thereof, wherein, A 1-A 3, Cy and R 1-R 2 are defined herein. The compounds of Formula I are kinase inhibitors. Therefore, the compounds of the disclosure can be used to treat clinical conditions caused by DDR function defects, such as cancers. (I)
    本公开提供了取代的咪唑[1,5-a]喹啉和相关化合物作为激酶抑制剂以及它们的用途。具体而言,本公开提供了公式I的化合物,或其药学上可接受的盐或前药,其中A1-A3,Cy和R1-R2在此被定义。公式I的化合物是激酶抑制剂。因此,本公开的化合物可用于治疗由DDR功能缺陷引起的临床疾病,如癌症。 (I)
  • Use of hydroxylamine derivatives, and method and preparations for increasing the tolerance of field crops against weather stresses
    申请人:——
    公开号:US20010051630A1
    公开(公告)日:2001-12-13
    This invention relates to the use of hydroxylamine derivatives of general formula (I), wherein R 1 represents phenyl, N-heteroaryl, S-heteroaryl or a naphthyl group any of which may be unsubstituted or substituted, an unsubstituted or substituted phenylamino or alkylamino or lower alkoxy; X represents halo, amino or an unsubstituted or substituted phenylamino group, or amino substituted with one or two lower alkyl or a hydroxy group, provided that if R 1 represents unsubstituted or substituted phenylamino, alkylamino or lower alkoxy, then X is not halo; Y represents hydrogen, hydroxy or alkanoyloxy, with the proviso that simultaneously R 1 may not represent phenyl, halophenyl, alkoxyphenyl, N-heteroaryl or naphthyl, X may not represent halo, hydroxy or amino and Y may not represent hydrogen or hydroxy; R 2 and R 3 , independently from each other, represent hydrogen or lower alkyl group, provided that R 2 and R 3 are not hydrogen simultaneously, or R 2 and R 3 along with the adjacent nitrogen atom form a 5- to 7-membered saturated hetero ring, to increase the tolerance of cultivated plants against weather condition stresses, such as cold, frost and drought.
    本发明涉及使用羟胺衍生物的一般式(I),其中R1代表苯基、N-杂环基、S-杂环基或萘基,其中任何一个可能未取代或取代,未取代或取代的苯氨基或烷基氨基或较低的烷氧基;X代表卤素、氨基或未取代或取代的苯氨基基团,或取代一或两个较低的烷基或羟基的氨基,但如果R1代表未取代或取代的苯氨基、烷基氨基或较低烷氧基,则X不是卤素;Y代表氢、羟基或脂肪酰氧基,但同时R1不能表示苯基、卤苯基、烷氧基苯基、N-杂环基或萘基,X不能表示卤素、羟基或氨基,Y不能表示氢或羟基;R2和R3相互独立地代表氢或较低的烷基,但要求R2和R3不能同时为氢,或者R2和R3与相邻的氮原子一起形成5-至7-成员的饱和杂环,以提高栽培植物对天气条件胁迫,如寒冷、霜冻和干旱的耐受性。
  • [EN] HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF<br/>[FR] DERIVES D'HYDROXYLAMINE UTILISES POUR AMELIORER LA PRODUCTION DE CHAPERONS MOLECULAIRES ET LEUR PREPARATION
    申请人:BIOREX KUTATÓ ÉS FEJLESZTÓ RT.
    公开号:WO1997016439A1
    公开(公告)日:1997-05-09
    (EN) A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, a hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which a hydroxylamine derivative is administered is a eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.(FR) Procédé visant à accroître l'expression d'un chaperon moléculaire par une cellule et/ou à intensifier l'activité de celui-ci dans les cellules. Le procédé consiste à traiter une cellule qui est exposée à une tension physiologique induisant l'expression d'un chaperon moléculaire par la cellule avec une quantité efficace d'un certain dérivé d'hydroxylamine afin d'augmenter la tension. Selon une autre variante, un dérivé d'hydroxylamine peut être administré à une cellule avant d'être exposé à une tension physiologique induisant l'expression d'un chaperon moléculaire par la cellule. De préférence, la cellule dans laquelle est administré le dérivé d'hydroxylamine est une cellule eucaryote. Le dérivé d'hydroxylamine correspond aux formules (I) et (II). L'invention se rapporte également à des nouveaux dérivés d'hydroxylamine relevant des formules (I) et (II), ainsi qu'à des compositions pharmaceutiques et/ou cosmétiques comprenant ces composés.
    本发明提供了一种增加细胞分子伴侣表达和/或增强细胞中分子伴侣活性的方法。该方法包括使用一定量的某种羟胺衍生物处理受到诱导细胞分子伴侣表达的生理压力的细胞,以增加压力。或者,在细胞暴露于诱导细胞分子伴侣表达的生理压力之前,可以向细胞中注入羟胺衍生物。最好注入羟胺衍生物的细胞是真核细胞。该羟胺衍生物对应于式(I)或(II)。本发明还提供了在式(I)和(II)范围内的新的羟胺衍生物,以及包含这些化合物的药物和/或化妆品组合物。
  • Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof
    申请人:Biorex Research & Development Co.
    公开号:US20040067940A1
    公开(公告)日:2004-04-08
    A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
    提供了一种通过细胞增加分子伴侣表达和/或增强细胞中分子伴侣活性的方法。该方法包括使用一定量的某种羟胺衍生物处理受到诱导细胞分子伴侣表达的生理应激的细胞,以增加应激。或者,在细胞暴露于诱导其表达分子伴侣的生理应激之前,可以向细胞施用羟胺衍生物。最好,施用羟胺衍生物的细胞是真核细胞。羟胺衍生物对应于式(I)或(II)。该发明还提供了落在式(I)和(II)范围内的新羟胺衍生物,以及包含上述化合物的药物和/或化妆品组合物。
  • 3-(substituted propylidene)-2-azetidinone derivates for blood platelet
    申请人:Taisho Pharmaceutical Co., Ltd.
    公开号:US04952689A1
    公开(公告)日:1990-08-28
    A 2-azetizinone derivative represented by the formula: ##STR1## wherein R.sup.1 is a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or an alkoxycarbonyl group in which the alkoxy group has 1 to 4 carbon atoms, R.sup.2 is a group represented by the formula ##STR2## a pyrrolidinyl group or a tetrahydroazepinyl group, and n is an integer of from 2 to 10, and a salt thereof are disclosed. These compounds are useful as blood platelet aggregation inhibiting agent.
    公开了一种由以下式表示的2-氮杂环酮衍生物:##STR1## 其中R.sup.1是卤素原子,具有1到4个碳原子的烷基,具有1到4个碳原子的烷氧基或烷氧羰基,其中烷氧基具有1到4个碳原子,R.sup.2是由以下式表示的基团##STR2##吡咯烷基或四氢唑烷基,n为2到10的整数,以及其盐。这些化合物可用作血小板聚集抑制剂。
查看更多